Actualités

Norway’s fund also publicly declared owning a 0.05% stake in SpaceX.

Elon Musk just declared his latest AI model objectively number one in intelligence, speed, and cost, and the timing could not be worse for two companies that Microsoft is betting billions on.

The band the options market prices for the next ten months runs from just under the low this stock has set over the past year to a level far above today's price, and the volatility behind it is close to what the stock has actually been doing.

A Washington tax proposal targeting inflation adjustments on capital gains could reshape what Elon Musk eventually owes on his massive Tesla stake, but the math reveals a far messier picture than the headlines suggest.

Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.

<p>Goldman Sachs will acquire NEOS Investments in a deal worth up to $2.25 billion, adding $30 billion in options-based income ETFs and vaulting Goldman Sachs Asset Management into the ranks of top-eight active ETF issuers.</p>

Missile shortages and a Pentagon production push could boost Lockheed Martin, RTX and defense ETFs as replenishment drives new orders.

Checks are being mailed from Grubhub's $23.8 million fine from the FTC after it settled allegations over its business practices.

DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.

By Amina Niasse NEW YORK, Aug 12 (Reuters) - Hims & Hers Health plans to offer some legally available peptides in 2026, but investors and analysts who spoke to Reuters after the telehealth company's

AI infrastructure stocks rose on Wednesday after strong quarterly financial reports from AI server hardware maker Super Micro Computer Inc. (NASDAQ:SMCI) and neocloud providers CoreWeave, Inc. (NASDAQ:CRWV) and Nebius Group NV (NASDAQ:NBIS). Big Tech companies have already signaled that spending on AI would not slow down. The combined outlays are set to surpass $730 billion […]

ISRG's US procedure growth slows in Q2, but ACA-related care deferrals may prove temporary as underlying demand and da Vinci 5 adoption remain strong.

UnitedHealth's lower medical costs are fueling an earnings recovery, but rising commercial costs and 2027 pricing decisions could test its durability.

DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.

Rocket Lab is growing fast, with a record backlog and rising revenue, but a possible Neutron delay is weighing on RKLB stock. So, where does the stock go from here?

Two healthcare giants, two very different dividend bets: one built on six decades of unbroken raises and a fortress balance sheet, the other dangling a fatter yield while racing to outrun its own blockbuster's collapse. Knowing which risk you are actually buying changes everything.

Geospatial technology provider Trimble (NASDAQ:TRMB) will be reporting results this Wednesday before market open. Here’s what you need to know.

PYPL's Venmo posts mid-teens TPV growth, but rising product adoption and monetization determine how much of that activity becomes revenue.

The congresswoman is raising awareness of the exorbitant costs and nitty-gritty details of egg freezing.

CEO KR Sridhar may have overstated the company's place within the industry, but his bigger point still stands.

General Motors has reached a supply chain agreement with Procura Auto Parts worth $4.5 billion, led by JPMorgan Chase and Banco Santander.

Bank of America (NYSE:BAC) said on August 12 that it will deploy $250 billion by July 2027 to finance US digital and infrastructure projects, from data centers to power grids to natural gas pipelines. The bank calls it the Critical Infrastructure Finance Initiative, arriving while the stock already carries a track record of outgrowing its […]

Materials and photonics company Coherent (NYSE:COHR) will be announcing earnings results this Wednesday after the bell. Here’s what investors should know.

The race to build artificial-intelligence infrastructure is fueling demand for new warehouses. Warehouse developer and operator Link Logistics said 15% of new leasing so far this year is tied to the data-center buildout, up sharply from a year earlier. Luke Petherbridge, chief executive of the Blackstone-owned company, said tenants include companies assembling and supplying components such as turbines, generators and switchgear.

Hello, Reader. Contrarian investing naturally draws a lot of heat for going “against” market trends, and sometimes for good reason. Simply being a contrarian without purpose is a losing strategy. That is why, although some of my recommendations can seem “against” the grain, I consider myself an opportunistic investor.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Many of the most successful investment recommendations of my career came from stocks that Wall Street had written off

<p>While U.S. ETF assets under management and flows rose to record levels in the first half of 2026, asset managers split the field with inflows from each constituency. Some continue to compete on price, but others are betting that investors will pay a premium for stellar short-term performance.</p>

Teledyne Technologies (NYSE: TDY) agreed to acquire Varex Imaging for US$1.1b, expanding its X ray and CT detector portfolio. The deal adds photon counting CT detector technology and oncology detectors to Teledyne's medical imaging capabilities. Both companies' boards unanimously approved the transaction, which involves minimal technology overlap and targets global OEM customers. This move by Teledyne Technologies highlights how digital imaging and healthcare instrumentation tie into...

Solar and storage demand surges in Europe as company returns to operating profitability.

Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses on translational research to speed up biomarker discovery and support precision oncology development. The AI tools are intended to help standardize and accelerate analysis of tumor samples across Gilead’s oncology pipeline. Gilead is not the only company leaning into AI to reshape drug discovery and development, so...

CrowdStrike Holdings (CRWD) is back in focus after its Fal.Con 2026 cybersecurity conference sold out faster than any prior year, signaling strong industry engagement around its Falcon platform and AI focused security offerings. See our latest analysis for CrowdStrike Holdings. Fal.Con 2026 adds to a series of AI security headlines for CrowdStrike Holdings, and investors have reacted with strong buying interest. A 30 day share price return of 18.55% has contributed to a year to date share...